Sudeep Pharma Q2 FY27 Earnings Call: First Non-Chinese Iron Phosphate Producer, PFN Revenue Jumps 57% (SUDEEPPHRM)

Sudeep Pharma Ltd held its Q2 FY27 earnings call on October 28, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Record Quarter, But PAT Growth Trails EBITDA

• Revenue Rs.196.7 crore — highest-ever quarter, up 21% YoY (vs Rs.162.7 crore in Q2 FY 2025-2026) and 24% QoQ (vs Rs.158.3 crore in Q1 FY 2026-2027).
• EBITDA Rs.73.2 crore at 37.2% margin — up 32% YoY and 33% QoQ; margin expanded from 34.1% in Q2 FY 2025-2026 and 34.7% in Q1 FY 2026-2027.
• PAT Rs.51.8 crore (26.3% margin) — up 28% QoQ but YoY growth trailed EBITDA due to other income lower by Rs.6 crore and an effective tax rate of 27% vs ~21% in Q2 FY 2025-2026, driven by higher depreciation on newly capitalized assets and PFN's ~28% average tax rate.
• H1 FY 2026-2027 revenue Rs.355 crore — up 23% YoY; EBITDA Rs.128.1 crore (36.1% margin, up 29% YoY); PAT Rs.92.4 crore, up 18% YoY.
• Exports ~65% of revenue — exports up 24% YoY; domestic ~35% in Q2 FY 2026-2027.
• Cost headwinds — S&D expense ran ~Rs.8 crore above normal on elevated sea freight (absorbed, not passed to customers); greenfield plant capitalized in the quarter with expenses now charged to P&L, plus certain SAM expenditures.
• Net debt Rs.72.5 crore — net debt/equity ~0.07x as of 30 September 2026 (vs Rs.33.6 crore / 0.04x at 31 March 2026); FY 2026-2027 capex ~Rs.77 crore, mainly the Dahej battery project and greenfield completion.

PFN Surges; Specialty Dragged by Fortified Rice Pause

• PFN revenue Rs.142 crore, +57% YoY — ~72% of consolidated revenue; segment EBITDA margin ~41% vs 33% in Q2 FY 2025-2026 with segment EBITDA nearly doubling; volume grew ~30-35% in Q2 and ~19% in H1 FY 2026-2027; growth broad-based across India, Africa, APAC and Europe.
• Specialty Ingredients Rs.54 crore, -25% YoY — +9% QoQ; the Government of India's Fortified Rice Program is temporarily paused with no visibility on restart during FY27; the program contributed ~20-25% of specialty revenue (~Rs.40-50 crore) in FY 2025-2026.
• Specialty margin at 28% — significantly lower YoY on operating leverage (limited premix revenue plus NSS drag); management expects new Q3-Q4 FY 2026-2027 contracts to carry better margins than the fortified rice business.
• Non-fortified premix visibility — management has "very good visibility" that Q3-Q4 FY 2026-2027 non-fortified rice demand will almost entirely offset the fortified rice loss and grow the category, without assuming a restart.
• Nandesari PFN site at ~80% utilization — optimum for core phosphates as of Q2 FY 2026-2027; the greenfield facility received FDA approval in Q2 FY 2026-2027 (approval came only the week before the call) with zero contribution in Q2; commercial supplies expected from H2 FY27, small quantities possibly in Q3 FY 2026-2027.
• Greenfield utilization of 10-15% expected in FY 2027-2028 — ramping faster in years 2-3; management targets 15-20% utilization in FY28 and ~75% optimum over 3-4 years, at which ~3x asset turnover is expected.

Magnesium Bisglycinate Emerges as a Rs.100 Crore+ Opportunity

• Q1 FY27 bisglycinate sales exceeded full-year FY26 sales — momentum continued in Q2 FY 2026-2027; average realization is more than 3x the PFN portfolio average; a dedicated brand, "Max Zorbis," is planned.
• Global TAM of ~$1 billion — management sized the magnesium bisglycinate ingredient opportunity at ~$1 billion, with 40-45% (~$400-450 million) from the US alone (period unspecified); 4-5 large US tolling/contract manufacturers hold ~50% of US demand, and Sudeep has approvals with 2 of the largest.
• Approvals: ~8-9 in the US, ~30-35 globally — including India and Europe as of the Q2 FY 2026-2027 call; 40% of Nandesari capacity is allocated to bisglycinate, gluconate and citrate, with 70-80% of that expected to go to bisglycinate.
• Top-3 PFN revenue contributor targeted over 2-3 years — management expects magnesium bisglycinate to reach north of Rs.100 crore from the ingredient alone by ~FY 2029-2030; citrates and gluconates combined could be a similar ~Rs.100 crore opportunity over the same view.
• GLP-1-driven demand thesis — management is developing citrates and sulfates for clinical/adult nutrition, noting GLP-1 patients (Ozempic, Mounjaro) typically skip meals, driving higher protein plus vitamin/mineral requirements; development is underway for certain very large customers.
• No binding volume contracts yet — customers have 10+ year relationships with Sudeep and are still developing their own products; Sudeep's demand is expected to scale only as those customers' products scale, making scale-up timing hard to predict.

Ex-China Iron Phosphate Moat; Binding Contracts Targeted Q4 FY27

• First and only non-Chinese producer at scale — management stated China produces 100% of battery-grade iron phosphate globally (close to 5 million tons as of Q2 FY 2026-2027); Sudeep claims an 18-24 month head start over any new entrant starting now, using proprietary green chemistry competitive on OPEX.
• Process barriers to replication — conventional Chinese chemistry generates 15,000 liters of effluent per metric ton, limiting conventional-process players in India to roughly 10,000-15,000 tons; Sudeep's process has cut effluent by 90% and solid waste by ~95%; an 11-year learning curve since 2018, 4 years of process development and ~2 years of customer validation are cited as barriers.
• Phase 1 of 25,000 tons on track for commissioning by April FY 2027-2028 — binding commitments targeted for signing in Q4 FY 2026-2027; management sees strong demand supporting the first 100,000 tons of annual capacity, with expansion discussions toward 200,000 tons (period unspecified) progressing faster than expected across the US, Korea, Europe and India.
• US 45X credit framework — US regulation requires cell manufacturers to use a PFE-compliant supply chain to be eligible for the 45X credit of $35 per kWh of US cell capacity; customers are willing to pay a premium for PFE-compliant supply, a framework under which India benefits. Sudeep's raw material supply for up to 100,000 tons is secured largely from India, with Morocco, Israel, Vietnam and Mexico cited as additional geographies; sourcing for the 200,000-ton requirement (period unspecified) will also be entirely ex-China.
• ~5-7 large customers targeted — including large Korean customers in Korea, Europe and the US; Korea is the key market given existing LFP/cathode capacity and Korean cell companies' US presence; Europe progress with specific customers. Validation of the Dahej site is assumed to take 3-6 months, with ~6 months of FY 2027-2028 before commercial supplies begin.
• Returns framework, not margins — management declined to guide EBITDA margins for the battery business but is targeting asset turnover close to 3x (period unspecified) and a similar ROCE profile; initial 1 lakh ton capex was cited at ~Rs.600 crore (period unspecified), with ROCEs targeted in line with FY26-and-earlier levels, noting FY27 may not reflect this.

37%+ Margins Aided by Phosphoric Acid Pass-Through; WC Days Elevated

• Q2 margins of 37%+ aided by phosphoric acid pass-through — structured on contracts signed in Q1 FY 2026-2027; phosphoric acid was up ~40% vs Q4 FY 2025-2026 levels as of Q1 FY 2026-2027 and has strengthened further; Q1-built inventory supports the business through October-November (Q3 FY 2026-2027).
• No further margin strengthening expected — management's goal is to sustain ~37% levels; any improvement will be assessed only after the new contracting cycle (period unspecified).
• Margin caveats — the newly capitalized greenfield plant will initially operate at lower utilization while incurring operating costs, and battery costs will start flowing into the P&L as commercialization approaches.
• Net working capital days at 214 — as of 30 September 2026, similar to end-FY 2025-2026; inventory includes a strategic stock-up of key raw materials such as purified phosphoric acid given the geopolitical situation, plus battery-project materials.
• 170-180 days target for FY 2026-2027 — excluding battery business inventory (officially reported consolidated results will include those inventory numbers); management is committed to ~150 days over a longer period (period unspecified); H1 FY 2026-2027 operating cash flow was Rs.43.5 crore, up Rs.26 crore YoY.
• Annualized H1 ROCE of 22.4% and ROE of 19% — tempered by capital deployed into the greenfield facility and SAM, which are not yet revenue-generating; management expects ROCE to improve as these projects commence operations and scale up (period unspecified).

Flattish NSS in FY27; Growth Levers Stack Into FY28

• Specialty expected to return to positive YoY growth in Q3-Q4 FY27 — based on customer contracts and new business alone, not assuming a fortified rice restart; Q2 FY27 brought approvals across infant nutrition, dietary supplements and human nutrition with commercial revenue expected from Q3 FY27.
• NSS guided flattish for FY27 — no significant growth expected; approvals from 5 customers (with ~12 customer projects in evaluation/development) are expected to support growth in FY28 and FY29, with FY28 NSS growth conservatively envisaged at a pace similar to the core business's current growth rate.
• NSS EBITDA margin target of ~30% in FY28 — aided by supply chain optimization from India and contingent on no additional supply-side challenges or shocks; customer reach is broadening beyond Ireland with increased sourcing from India.
• Bisglycinate volumes to scale from Q4 FY 2026-2027 — commercial supplies have started to select customers (capacity-constrained); management will not account for Q3 FY 2026-2027 but expects sizable volumes to customers in India and globally starting Q4 FY 2026-2027; PFN greenfield contribution expected to rise to 10-20% from Q4 FY 2026-2027 and Q1 FY 2027-2028 onwards.
• Battery offtake disclosure within two months — management will share customer-wise binding agreement volumes on the next call or within two months, with more specifics possibly at the Q3 FY 2026-2027 call; investment pace to remain aligned with firm customer commitments under disciplined capital allocation.
• PFN mid-to-long-term FDA tailwind — management expects the Nandesari FDA approval to aid PFN growth not just over Q3-Q4 FY 2026-2027 but on a mid-to-long-term basis; management stated its focus on high-value products, pricing discipline and operational efficiency positions the company to meet its growth objectives for FY 2026-2027.